How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Hepatitis Testing Diagnosis Market
- By Test Type: Serological Tests, Molecular Tests (PCR), Liver Function Tests, Rapid Diagnostic Tests (RDTs), Genotyping Tests
- By Hepatitis Type: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E
- By End User: Hospitals, Diagnostic Laboratories, Clinics, Blood Banks, Research Institutes
- By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Polymerase Chain Reaction (PCR), Lateral Flow Immunoassay, Next-Generation Sequencing (NGS)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Serological Tests leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Hepatitis Testing Diagnosis Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Hepatitis Type 5
End User 5
Technology 5
Companies profiled
Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
bioMérieux
F. Hoffmann-La Roche AG
Ortho Clinical Diagnostics
Becton Dickinson and Company (BD)
Thermo Fisher Scientific
Hologic Inc.
Quidel Corporation
DiaSorin S.p.A.
Bio-Rad Laboratories
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →bioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ortho Clinical Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Quidel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →DiaSorin S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sekisui Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Alere Inc. (now part of Abbott)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →LumiraDx
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,443M by 2033 · 3.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Serological Tests32.6
- Molecular Tests (PCR)16.1
- Liver Function Tests20.2
- Rapid Diagnostic Tests (RDTs)16.9
- Genotyping Tests14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$592.1M → $823.3M · 4.2%
Europe$412.7M → $619.0M · 5.2%
Asia Pacific$376.8M → $523.0M · 4.2%
Latin America$233.2M → $335.6M · 4.7%
Middle East and Africa$179.4M → $217.3M · 2.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.892026
3.892027
3.922028
3.922029
3.942030
3.952031
3.972032
3.972033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories15.9
- Roche Diagnostics23.2
- Siemens Healthineers5.0
- bioMérieux11.1
- F. Hoffmann-La Roche AG6.3
- Ortho Clinical Diagnostics10.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type19.8%
Hepatitis Type15.4%
End User39.1%
Technology25.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe24.6
- Asia Pacific20.8
- Latin America13.3
- Middle East and Africa8.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 93 | 73 | 75 | 80 | 86 | 94 | 84 |
| Roche Diagnostics | 93 | 73 | 86 | 90 | 70 | 81 | 82 |
| Siemens Healthineers | 74 | 87 | 67 | 71 | 76 | 73 | 75 |
| bioMérieux | 78 | 68 | 79 | 62 | 65 | 80 | 72 |
| F. Hoffmann-La Roche AG | 74 | 55 | 61 | 52 | 57 | 57 | 59 |
| Ortho Clinical Diagnostics | 64 | 64 | 64 | 51 | 64 | 69 | 63 |
| Becton Dickinson and Company (BD) | 58 | 64 | 52 | 50 | 55 | 49 | 55 |
| Thermo Fisher Scientific | 58 | 43 | 54 | 44 | 51 | 38 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | − | ◐ | ◐ | ✓ |
| Roche Diagnostics | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| bioMérieux | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| F. Hoffmann-La Roche AG | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| Ortho Clinical Diagnostics | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Becton Dickinson and Company (BD) | ◐ | − | ◐ | − | − | − |
| Thermo Fisher Scientific | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories84
2Roche Diagnostics82
3Siemens Healthineers75
4bioMérieux72
5Ortho Clinical Diagnostics63
6F. Hoffmann-La Roche AG59
7Becton Dickinson and Company (BD)55
8Thermo Fisher Scientific48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesRoche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Siemens HealthineersbioMérieux
Contender2
Focused players with pockets of strength.
F. Hoffmann-La Roche AGOrtho Clinical Diagnostics
Niche2
Specialists in a single segment or region.
Becton Dickinson and Company (BD)Thermo Fisher Scientific
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Hepatitis Testing Diagnosis Market — a $130M beachhead inside a $1.97B market.
Beachhead (SOM)$130Mobtainable near-term
Serviceable (SAM)$769Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Serological Tests
Best fit — highest urgency & budget in Test Type.
Economic buyer78 fit
Molecular Tests (PCR)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Liver Function Tests
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Hepatitis Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel25%
Digital / self-serve20%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hepatitis Testing Diagnosis Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation11%
Closed-won8%
$15.8KCAC
$63KLTV
4.0:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hepatitis Testing Diagnosis Market is a high-growth opportunity — $10.3B by 2033, compounding at 10.7%.
TAM · 2025$4.57Btoday
TAM · 2033$10.3Bforecast
CAGR10.7%2027–2033
Cumulative$64.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.3BTotal addressable market
SAM$3.64BServiceable available market
SOM$768MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.7% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.3BLarge & growingTAM by 2033 at 10.7% CAGR
$3.64BServiceable nowreachable with today’s model
$768MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.04BBear7.0% CAGR
$10.3BBase10.7% CAGR
$13.2BBull14.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Hepatitis Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hepatitis Testing Diagnosis Market — a $6.83B market by 2033. Plan: grow share from 7.4% to 14.1%.
Market size · 2033$6.83Btotal addressable
Market CAGR8.0%2027–2033
Target share14.1%from 7.4% today
Revenue ambition$963Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 14.1% | Behind |
| Revenue | $461M | $963M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.3% | 39.1% | Ahead |
| Customer retention | 86.2% | 93.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Hepatitis Type capability
A defensible second engine — invest in Hepatitis Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Hepatitis Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in Hepatitis Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hepatitis Testing Diagnosis Market conversation — a $3.79B market you can size, segment and defend in minutes.
Market size · 2033$3.79Btotal opportunity
Growth9.4%CAGR to 2033
Addressable buyers909+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$91K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsSiemens HealthineersbioMérieuxF. Hoffmann-La Roche AGOrtho Clinical DiagnosticsBecton Dickinson and Company (BD)Thermo Fisher Scientific+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hepatitis Testing Diagnosis Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hepatitis Testing Diagnosis Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hepatitis Rapid Testing Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportHepatitis E Virus IgM Antibody Detection Kit Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportHepatitis E Virus IgG Antibody Detection Kit Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportFacial Injectors Market
Market size, share, segmentation and regional forecast.
$564M market · 2025 base year
View reportHepatitis C Virus Test Kit Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportHepatitis C Virus Testing Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportHepatitis C Virus Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportHepatitis C Virus Genotyping Detection Kit Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHepatitis C Virus Drugs Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportHepatitis C Virus Antigens Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportHepatitis C Virus Antibody ELISA Test Kit Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportHepatitis C Treatment Drug Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.